*pharmaceuticals*

MDPI

*Correction*

# Correction: Pan et al. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. *Pharmaceuticals* 2025, *18*, 1159

**Tianshu Pan [1,2,3], Olawale A. Alimi [1,2], Bo Liu [1,2], Mena A. Krishnan [1,2], Mitchell Kuss [1,2], Wei Shi [1,2], Jairam Krishnamurthy [4], Jianghu James Dong [5], Rebecca E. Oberley-Deegan [3,*] and Bin Duan [1,2,6,7,*]**

1 Mary & Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha, NE 68198, USA; tpan@unmc.edu (T.P.); oalimi@unmc.edu (O.A.A.); bo.liu@unmc.edu (B.L.); mekrishnan@unmc.edu (M.A.K.); mitchell.kuss@unmc.edu (M.K.); weshi@unmc.edu (W.S.)
2 Division of Cardiology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA
3 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
4 Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA; jairam.krishnamurthy@hsc.utah.edu
5 Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE 68198, USA; jianghu.dong@unmc.edu
6 Department of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA
7 Department of Mechanical and Materials Engineering, University of Nebraska-Lincoln, Lincoln, NE 68588, USA
* Correspondence: becky.deegan@unmc.edu (R.E.O.-D.); bin.duan@unmc.edu (B.D.)

## Citation Correction

In the original publication [1], Section "3. Discussion". Original sentence: "In ovarian cancer models, co-treatment with BMX-001 and PTX significantly reduced the cell viability of CAOV2 cells compared to PTX alone and downregulated the expression of BCL2, NF-κB, and IL-1β [49]."

Original citation for [49] is "Batinic-Haberle, I.; Tovmasyan, A.; Veade, A.; Spasojevic, I.; Reihani, S.; Secord, A. Mn porphyrin/ascorbate sensitizes serous epithelial ovarian cancer to chemotherapy. *Free. Radic. Biol. Med.* **2018**, *128*, S74–S75." It has been correctly replaced with [2].

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

## References

1. Pan, T.; Alimi, O.A.; Liu, B.; Krishnan, M.A.; Kuss, M.; Shi, W.; Krishnamurthy, J.; Dong, J.J.; Oberley-Deegan, R.E.; Duan, B. Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. *Pharmaceuticals* **2025**, *18*, 1159. [CrossRef] [PubMed]
2. Spasojevic, I.; da Silva, W.T.A.; Huang, Z.; Duan, W.; Du, L.; Chen, C.; Cao, J.; Zhang, S.; Lee, H.; Lo, G.; et al. Redox-active Mn porphyrin-based clinical candidate, MnTnBuOE-2-PyP5+ (BMX-001) reduces paclitaxel-induced neuropathy, while suppressing ovarian cancer growth. *Free Radic. Biol. Med.* **2024**, *224*, S54–S55. [CrossRef]

Check for updates

Received: 3 February 2026
Accepted: 9 February 2026
Published: 25 February 2026

**Copyright:** © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.